C4 Therapeutics
Founded Year
2016Stage
IPO | IPOTotal Raised
$243MDate of IPO
10/2/2020Market Cap
0.15BStock Price
3.02About C4 Therapeutics
C4 Therapeutics (NASDAQ: CCCC) advances a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of cells.
Missing: C4 Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: C4 Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Research containing C4 Therapeutics
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned C4 Therapeutics in 1 CB Insights research brief, most recently on Aug 3, 2021.
Expert Collections containing C4 Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
C4 Therapeutics is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
C4 Therapeutics Patents
C4 Therapeutics has filed 31 patents.
The 3 most popular patent topics include:
- Proteins
- Transcription factors
- Clusters of differentiation
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
11/24/2020 | 4/11/2023 | Transcription factors, Proteins, Cell biology, Clusters of differentiation, G protein coupled receptors | Grant |
Application Date | 11/24/2020 |
|---|---|
Grant Date | 4/11/2023 |
Title | |
Related Topics | Transcription factors, Proteins, Cell biology, Clusters of differentiation, G protein coupled receptors |
Status | Grant |
Latest C4 Therapeutics News
Apr 19, 2023
04/19/2023 | 07:01am EDT Message : *Required fields WATERTOWN, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that C4T management will participate in a fireside chat at the Stifel 2023 Virtual Targeted Oncology Days. Fireside Chat Details: Date/Time: Wednesday, April 26th, 2023 at 11:00 AM ET A live webcast will be available on the Investors section of the company’s website at www.c4therapeutics.com . An archived replay of the webcast will be available for approximately 30 days following the live event. About C4 Therapeutics C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines that harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. C4T is advancing multiple targeted oncology programs to the clinic and expanding its research platform to deliver the next wave of medicines for difficult-to-treat diseases. For more information, please visit www.c4therapeutics.com . Investor Contact:
C4 Therapeutics Frequently Asked Questions (FAQ)
When was C4 Therapeutics founded?
C4 Therapeutics was founded in 2016.
Where is C4 Therapeutics's headquarters?
C4 Therapeutics's headquarters is located at 490 Arsenal Way, Watertown.
What is C4 Therapeutics's latest funding round?
C4 Therapeutics's latest funding round is IPO.
How much did C4 Therapeutics raise?
C4 Therapeutics raised a total of $243M.
Who are the investors of C4 Therapeutics?
Investors of C4 Therapeutics include Perceptive Advisors, Cobro Ventures, Yonjin Venture, Taiwania Capital, T. Rowe Price and 22 more.
Who are C4 Therapeutics's competitors?
Competitors of C4 Therapeutics include Pin Therapeutics and 2 more.
Compare C4 Therapeutics to Competitors
Amphista Therapeutics is a biopharmaceutical company that creates cancer therapeutics to help harness the body's natural processes to selectively degrade and remove disease-causing proteins. It leverages cell's degradation machinery to modulate the abundance of proteins that are responsible for disease progression. The company was founded in 2017 and is based in Cambridge, U.K.
BioTheryX is a clinical-stage biopharmaceutical company focused on restoring protein homeostasis through protein modulation, including protein degradation as well as multi-kinase inhibition, to develop treatments that extend and improve the quality-of-life of patients with life-threatening diseases.
Pin Therapeutics is a pharmaceutical company that creates therapeutic products based on chemical biology-driven protein degradation, including PROTAC technology. The company aims to develop PROTAC compounds for oncology, neurodegenerative diseases, and cardiovascular indications based on disease-agnostic approaches.
FIMECS is a drug discovery biotech firm focused on developing protein degradation therapeutics for cancers and other difficult-to-treat diseases.
Kangpu Biomedical is a biopharmaceutical company in the clinical stage, focusing on cancer, autoimmune diseases, inflammation, and other therapeutic areas, mainly based on protein ubiquitination and the degradation and X-Synergy new drug combination technology platform and other proprietary patents.
Arvinas (NASDAQ: ARVN) is a pharmaceutical company focused on developing small molecules aimed at degrading disease-causing cellular proteins. The company is translating these protein degradation approaches into drugs for the treatment of cancer and other diseases. Many diseases are a result of "rogue," uncontrolled proteins, whose absence could bring great clinical benefit to patients.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.